NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

PureTech Health plc (PRTC) Stock Analysis

PureTech Health plc (PRTC) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

PRTC

$17.38

−$1.23 (−6.58%)

Last trade July 17, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare PRTC with… →

PRTC Key Statistics

As of Jul 17, 2026
Trading
Open
$16.87
Previous Close
$18.61
Day's Range
16.87–17.38
52-Week Range
14.50–19.92
Volume
9.86K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.79
Valuation
Market Cap
$419.90M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
90.13
EPS (ttm)Profit attributable to each share over the last twelve months.
−4.60
Financials (FY)
Revenue (FY)
$4.66M+7.97%
Net Income (FY)
−$109.74M−305.08%
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
−6.05%
Dividend and dates
Avg Volume
9.35K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

PRTC Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+4.45%
2025−9.86%
2024 (partial year)−12.43%

As of July 17, 2026.

PRTC Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$4.66M−$109.74M−2355.4%
2024$4.32M$53.51M1240.1%
2023$750.00K−$65.70M−8759.6%
2022$2.09M−$50.35M−2409.3%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$4.66M—−$98.53M−$109.74M−2355.4%
2024$4.32M—−$136.10M$53.51M1240.1%
2023$750.00K—−$146.20M−$65.70M−8759.6%
2022$2.09M—−$197.81M−$50.35M−2409.3%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

PRTC Valuation vs Biotechnology Median

Median of 656 stocks
MetricPRTCBiotechnology medianvs median
P/S ratio90.1315.265.9x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

PureTech Health plc (PRTC) is capitalised at $419.90M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector.

The 52-week range on file runs from $14.50 to $19.92. PRTC last closed at $17.38 on July 17, 2026. That is −$1.23 (−6.58%) against the previous close. The latest close sits 19.86% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $4.66M. Against the prior fiscal year total of $4.32M, that is a change of +7.97%. The same year closed with a net loss of $109.74M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −4.6.

Across the 4 fiscal years on file, revenue moves from $2.09M in 2022 to $4.66M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 90.13. On price-to-sales that is 5.9 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 0.79. Annualized volatility over the trailing 1 year is 47.89%. The trailing one-year price return is −6.05%. The stored price history starts on December 19, 2024, and the total return since then is −17.56%.

Growth & Income

The record shows no dividend for PRTC.

So far in 2026 the price is +4.45%. The record holds one complete calendar year, 2025, which returned −9.86%.

Peer Comparison

PureTech Health plc (PRTC) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
PureTech Health plc PRTC $419.90M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. PureTech Health plc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of July 17, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About PureTech Health plc

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. The company also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development; oral therapies based on defined bacterial consortia that is in phase 3 clinical stage; and engineering hematopoietic stem cells to enable targeted therapies for patients with blood cancers. Further, it develops voice-based technology platform that detects changes in the sound of voice that are linked with health conditions, including depression, anxiety, and respiratory disease. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Visit website →